Diabetic nephropathy in the elderly - clinical practice

• Autorzy: Nadolnik K. , Skrypnik D. , Skrypnik K. , Bogdanski P.
• Języki publikacji: EN

Abstrakty

EN

Common health problems of the elderly in the near future will become even more common with aging of the population and longer average life expectancy. The elderly tend to have multiple disorders at one time, some of which may aggravate the course of others. One of the most common diseases, diabetes – “the epidemics of XXI century”, treatment of which costs approximately 11% of world health care budget – is the leading reason of chronic kidney disease and end-stage renal disease. Diabetic nephropathy can be a complication of both diabetes mellitus type 1 and 2. The most numerous group of patients with recently-made diagnosis are these above 60 years of age. Albuminuria, which, depending on its intensity, is one of the diagnostic criteria, can appear even in the process of aging itself. Overlapping of structural and functional changes that develop with age and those caused by diabetes is therefore a challenge, both diagnostic and clinical. There are certain methods of early diagnosis and prevention of progression of diabetic kidney disease. There is, however, no targeted treatment and existing therapies are generally based on glycemia and blood pressure control. Some patients in the advanced stage undergo dialyses just like in other kidney failure cases. The course of the disease is influenced by modifiable factors, such as protein and salt intake or cigarette smoking. In the light of the fact that this problem will concern an increasing number of patients, diagnostics and treatment can and should be introduced in the early stages of the disease. This all fits within the recently popular “healthy aging” ideology. Its popularization and implementation can bring measurable benefits of social and economic character.

PL

Problemy zdrowotne powszechne wśród osób starszych wkrótce staną się jeszcze bardziej rozpowszechnione w związku ze starzeniem się populacji oraz szacowaną coraz dłuższą średnią życia. Osoby w podeszłym wieku charakteryzuje posiadanie wielu chorób równocześnie, przy czym niektóre z nich mogą pogarszać przebieg pozostałych. Jedna z najczęstszych – cukrzyca – „epidemia XXI wieku”, na której leczenie przeznacza się około 11% światowego budżetu na ochronę zdrowia - jest wiodącą przyczyną przewlekłej choroby, a także schyłkowej niewydolności nerek. Cukrzycowa choroba nerek dotyka zarówno chorych na cukrzycę pierwszego, jak i drugiego typu. Najliczniejszą grupę pacjentów ze świeżą diagnozą stanowią ci powyżej 60. roku życia. Albuminuria, która, w zależności od nasilenia, jest jednym z kryteriów rozpoznania, pojawiać się może nawet w przebiegu samego procesu starzenia się organizmu. Nakładanie się pojawiających się wraz z wiekiem zmian struktury i funkcji nerek oraz zmian spowodowanych cukrzycą to zatem wyzwanie diagnostyczne oraz kliniczne. Istnieją określone metody wczesnego wykrywania oraz zapobiegania progresji cukrzycowej choroby nerek. Nie istnieje jednak celowane leczenie, a obecne terapie opierają się głównie na kontroli glikemii oraz ciśnienia tętniczego. Część pacjentów w zaawansowanym stadium jest poddawana dializom jak w innych przypadkach niewydolności nerek. Na przebieg choroby znaczny wpływ mają modyfikowalne czynniki, takie jak spożycie białka, soli, palenie tytoniu. W świetle faktu, że problem ten dotyczyć będzie coraz większej części społeczeństwa, diagnostyka i leczenie mogą i powinny być podejmowane już we wczesnych stadiach schorzenia. Wpisuje się to w ostatnio popularną ideologię „zdrowego starzenia się”, której popularyzacja i wprowadzanie w życie mogą przynieść wymierne korzyści społeczne, gospodarcze i ekonomiczne.

• Wydawca: -
• Czasopismo: Roczniki Państwowego Zakładu Higieny
• Rocznik: 2018
• Tom: 69
• Numer: 4
• Opis fizyczny: p.327-334,ref.

Twórcy

autor

Nadolnik K.

• Faculty of Medicine I, Poznan University of Medical Sciences, Poznan, Poland

autor

Skrypnik D.

• Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, Szamarzewskiego 82/84, 60-569 Poznan, Poland

autor

Skrypnik K.

• Institute of Human Nutrition and Dietetics, Poznan University of Life Science, Poznan, Poland

autor

Bogdanski P.

• Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, Szamarzewskiego 82/84, 60-569 Poznan, Poland

Bibliografia

• 1. United Nations: Political Declaration and Madrid International Plan of Action on Ageing 2002. Available at: http://www.un.org/en/events/pastevents/pdfs/ Madrid_plan.pdf (Accessed 14.05.2018)
• 2. European Commission: The social situation in the European Union 2005-2006. Available http://ec.europa.eu/employment_social/social_situation/docs/ssr2005_2006_en.pdf (Accessed 14.05.2018)
• 3. Ortman J.M.: U.S. Population Trends: 2000 to 2060: Webinar for the Minority Business Development Agency. US Department of Commerce 2014. Available https://www.mbda.gov/sites/mbda.gov/files/migrated/ files-attachments/Demographics_Webinar.pdf (Accessed 14.05.2018)
• 4. World Health Organization: World Report on Ageing and Health. WHO Press 2015. Available http://apps.who.int/iris/bitstream/handle/10665/186463/9789240694811_eng.pdf;jsessionid=787149ABB135949E56370D504243E73E?sequence=1 (Accessed 14.05.2018)
• 5. Marengoni A., Angleman S., Melis R., Mangialasche F., Karp A., Garmen A. et al.: Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011;10(4):430-439 doi:10.1016/j.arr.2011.03.003.
• 6. Chang A.M., Halter J.B.: Aging and insulin secretion. Am J Physiol Endocrinol Metab 2003;284(1):E7-12 doi:10.1152/ajpendo.00366.2002.
• 7. Laiteerapong, N., Karter, A. J., Liu, J. Y., Moffet, H. H., Sudore, R., Schillinger, D., John P.M., Huang, E. S.: Correlates of Quality of Life in Older Adults With Diabetes: The Diabetes & Aging Study. Diabetes Care 2011;34(8):1749–1753 doi:10.2337/dc10-2424.
• 8. Kalyani R.R., Corriere M., Ferrucci L.: Agerelated and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol 2014;2(10):819–829 doi:10.1016/S2213-8587(14)70034-8.
• 9. Ogurtsova K., da Rocha Fernandes J., Huang Y., Linnenkamp U., Guariguata L., Cho N.H., Cavan D., Shaw J.E., Makaroff L.E.: IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin 2017;128;40-50 doi:10.1016/j. diabres.2017.03.024.
• 10. United Nations General Assembly: Political declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. 2011 Available http://www.who.int/nmh/events/un_ncd_summit2011/political_declaration_ en.pdf (Accessed 14.05.2018)
• 11. da Rocha Fernandes J., Ogurtsova K., Linnenkamp U., Guariguata L., Seuring T., Zhang P., Cavan D., Makaroff L.E.: IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res Clin Pract 2016;117: 48-54 doi:10.1016/j.diabres.2016.04.016.
• 12. Cheung N., Mitchell P., Wong T.Y.: Diabetic retinopathy. Lancet 2010;376(9735):124-136 doi:10.1016/S0140-6736(09)62124-3.
• 13. Centers for Disease Control and Prevention (CDC) National Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United States. Atlanta, GA: U.S. Department of Health and Human Services, CDC 1999. Available https://www. cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf (Accessed 14.05.2018)
• 14. Chudek J., Wikarek T., Więcek A.: Epidemia przewlekłej choroby nerek w populacji osób w podeszłym wieku jako nakładanie się procesu fizjologicznego starzenia i nabytych uszkodzeń nerek [Epidemic of chronic kidney disease of the aging population — physiological aging and acquired kidney injuries]. Forum Nefrologiczne 2013;6(1):1-8 (in Polish).
• 15. Mazzone T., Chait A., Plutzky J.: Addressing cardiovascular disease risk in diabetes: insights from mechanistic studies. Lancet 2008;371(9626):1800-1809 doi:10.1016/S0140-6736(08)60768-0.
• 16. Kazancioğlu R.: Risk factors for chronic kidney disease: an update. Kidney Int Suppl 2013;3(4):368-371 doi:10.1038/kisup.2013.79.
• 17. Fox C.S., Larson M.G., Leip E.P., Culleton B., Wilson P.W.F., Levy D.: Predictors of New- Onset Kidney Disease in a Community-Based Population. JAMA 2004;291(7):844–850 doi:10.1001/jama.291.7.844.
• 18. Skrypnik K, Suliburska J, Skrypnik D, Pilarski Ł, Reguła J, Bogdański P.: The genetic basis of obesity complications. Acta Sci Pol Technol Aliment 2017;16(1):83-91 doi: 10.17306/J.AFS.2017.0442.
• 19. Polskie Towarzystwo Diabetologiczne: Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2017. Stanowisko Polskiego Towarzystwa Diabetologicznego [2017]. Guidelines on the management of diabetic patients. A position of Diabetes Poland]. Via Medica 2017;3(A).
• 20. Prevalence and control of cardiovascular risk factors in Poland. The NATPOL 2011 Survey.
• 21. Polskie Towarzystwo Nadciśnienia Tętniczego: Estymacja NATPOL 2020: opracowanie PTNT na bazie trendu 2002 – 2011 [NATPOL 2020 estimation: PTNT report basing on 2002 – 2011 trend] In: Narkiewicz K.: Nadciśnienie tętnicze 2013: Polska na tle świata [Arterial hypertension 2013: Polish compared to the rest of the world] Available www.who.un.org.pl/common/ files_download.php?fid=27 (Accessed 15.05.2018)
• 22. Henschen F.: On the term Diabetes in the works of Aretaeus and Galen. Med Hist 1969;13:190–192.
• 23. Feudtner C.: Bittersweet: Diabetes, Insulin and Transformation of Illness. Chapel Hill, University of North Caroline Press, 2003.
• 24. Lakhtakia R.: The History of Diabetes Mellitus. Sultan Qaboos Univ Med J 2013;13(3):368-370.
• 25. Ahmed A.M.: History of diabetes mellitus. Saudi Med J 2002;23(4):373-378.
• 26. Haneda, M., Utsunomiya, K., Koya, D., Babazono, T., Moriya, T., Makino, H., Kimura K., Suzuki Y., Wada T., Ogawa S., Inaba M., Kanno Y., Shigematsu T., Masakane I., Tsuchiya K., Honda K., Ichikawa K., Shide K. and Joint Committee on Diabetic Nephropathy: A new Classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy. J Diabetes Investig 2015;6(2):242–246 doi:10.1111/jdi.12319.
• 27. Florkowski C.M., Chew-Harris J.S.: Methods of Estimating GFR – Different Equations Including CKDEPI. Clin Biochem Rev 2011;32(2):75-79.
• 28. Kilbride H.S., Stevens P.E., Eaglestone G., Knight S., Carter J.L., Delaney M.P., Farmer C.K., Irving J., O’Riordan S.E., Dalton R.N., Lamb E.J.: Accuracy of the MDRD (Modification of Diet in Renal Disease) Study and CKD-EPI (CKD Epidemiology Collaboration) Equations for Estimation of GFR in the Elderly. Am J Kidney Dis 2013;61(1):57-66 doi: 10.1053/j.ajkd.2012.06.016.
• 29. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y., Castro A.F., Feldman H.I., Kusek J.W., Eggers P., Van Lente F., Greene T., Coresh J.: A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med 2009;150:604–612 doi:10.7326/0003-4819-150-9-200905050-00006.
• 30. Carter J.L., Stevens P.E., Irving J.E., Lamb E.J.: Estimating glomerular filtration rate: comparison of the CKD-EPI and MDRD equations in a large UK cohort with particular emphasis on the effect of age. QJM 2011;104(10):839-847 doi:10.1093/qjmed/hcr077.
• 31. Dharnidharka V.R., Kwon C., Stevens G.: Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40(2):221-226 doi:10.1053/ajkd.2002.34487.
• 32. Roos J.F., Doust J., Tett S.E., Kirkpatrick C.M.: Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children - a meta-analysis. Clin Biochem 2007;40(5-6):383-391.
• 33. Pan P., Binjie H., Min L., Lipei F., Yanli N., Junwen Z., Xianghua S.: A Meta-analysis on diagnostic value of serum cystatin C and creatinine for the evaluation of glomerular filtration function in renal transplant patients. Afr Health Sci 2014;14(4):1025-1035 doi:10.4314/ahs.v14i4.34.
• 34. Stevens P.E. Levin A., Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members: Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline. Ann Intern Med 2013;158(11):825-830 doi:10.7326/0003-4819-158-11-201306040-00007.
• 35. Parving H.H., Mauer M., Ritz E.: Diabetic nephropathy. In: Brenner B.M., Rector F.C. Brenner and Rector’s The Kidney. Philadelphia, Saunders, 2004.
• 36. Mathisen U.D., Melsom T., Ingebretsen O.C., Jenssen T., Njølstad I., Solbu M.D., Toft I., Eriksen B.O.: Estimated GFR Associates with Cardiovascular Risk Factors Independently of Measured GFR. J Am Soc Nephrol 2011;22(5):927-937 doi: 10.1681/ASN.2010050479.
• 37. Pontremoli R.: Microalbuminuria in essential hypertension - its relation to cardiovascular risk factors. Nephrol Dial Transplant 1996;11:2113-2134 doi:10.1093/oxfordjournals.ndt.a027119.
• 38. Renko M., Tapanainen P., Tossavainen P., Pokka T., Uhari M.: Meta-Analysis of the Significance of Asymptomatic Bacteriuria in Diabetes. Diabetes Care 2011;34(1):230-235 doi:10.2337/dc10-0421.
• 39. Koh K.H., Dayanath B., Doery J.C., Polkinghorne K.R., Teede H., Kerr P.G.: Effect of exercise on albuminuria in people with diabetes. Nephrology (Carlton) 2011;16(8):704-709 doi:10.1111/j.1440-1797.2011.01508.x.
• 40. 40.Cordonnier D.J., Pinel N., Barro C., Maynard M., Zaoui P., Halimi S., Hurault de Ligny B., Reznic Y., Simon D., Bilous R.W.: Expansion of cortical intersitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. J Am Soc Nephrol 1999;10(6):1253-63.
• 41. Arakawa M.: A scanning electron microscopy of the glomerulus of normal and nephrotic rats. Lab Invest 1970;23:489-496.
• 42. Friedman E.A.: Renal syndromes in diabetes. Endocrinol Metab Clin North Am 1996;25(2):293-324.
• 43. Denic A., Glassock R.J., Rule A.D.: Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis 2016;23(1):19-28 doi:10.1053/j. ackd.2015.08.004.
• 44. Goyal V.K.: Changes with age in the human kidney. Exp Gerontol 1982;17:321–331.
• 45. McLachlan M.S.: The ageing kidney. Lancet 1978;15:143–146.
• 46. Takazakura E., Sawabu N., Handa A., Takada A., Shinoda A., Takeuchi J.: Intrarenal vascular changes with age and disease. Kidney Int 1972; 2(4): 224–230.
• 47. Ljungqvist A., Lagergren C.: Normal intrarenal arterial pattern in adult and ageing human kidney. A microangiographical and histological study. J Anat 1962;96:285–300.
• 48. Kasiske B.L.: Relationship between vascular disease and age associated changes in the human kidney. Kidney Int 1987;31:1153–1159.
• 49. Hollenberg N.K., Adams D.F., Solomon H.S. Rashid A., Abrams H.L., Merrill J.P.: Senescence and the renal vasculature in normal man. Circ Res 1974;34:309–316.
• 50. Khan I.H., Catto G.R., Edward N., Macleod A.M.: Acute renal failure: factors influencing nephrology referral and outcome. QJM 1997;90:781–785.
• 51. Plante G.E.: Impact of aging on the body’s vascular system. Metabolism 2003;52(2):31-35.
• 52. Murata K., Horiuchi Y.: Age-dependent distribution of acidic glycosaminoglycans in human kidney tissue. Nephron 1978;20:111–118.
• 53. Cullen-McEwen L.A., Kett M.M., Dowling J., Anderson W.P., Bertram J.F.: Nephron number, renal function, and arterial pressure in aged GDNF heterozygous mice. Hypertension 2003;41:335–340.
• 54. Thomson S.C., Vallon V., Blantz R.C.: Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 2004;286:F8–F15.
• 55. Lindeman R.D., Tobin J.D., Shock N.W.: Association between blood pressure and the rate of decline in renal function with age. Kidney Int 1984;26:861–868.
• 56. Fliser D., Franek E., Joest M., Block S., Mutschler E., Ritz E.: Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int 1997;51:1196–1204.
• 57. McMurdo M.E.: A healthy old age: realistic or futile goal? Br Med J 2000;321:1149–1151.
• 58. James M.A., Fotherby M.D., Potter J.F.: Screening tests for microalbuminuria in non-diabetic elderly subjects and their relation to blood pressure. Clin Sci 1995;88:185–190.
• 59. United States Renal Data System: 2012 Atlas of CKD & ESRD. Available http://www.usrds.org/atlas.aspx (Accessed 14.05.2018)
• 60. Meier-Kriesche H.U., Port F.K., Ojo A.O., Rudich S.M., Hanson J.A., Cibrik D.M., Leichtman A.B., Kaplan B.: Effect of waiting time on renal transplant outcome. Kidney Int 2000;58(3):1311-1317 doi:10.1046/j.1523-1755.2000.00287.x.
• 61. Mange K.C., Joffe M.M., Feldman H.I.: Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001;344(10):726-731 doi:10.1056/NEJM200103083441004.
• 62. Kasiske B.L., Snyder J.J., Matas A.J., Ellison M.D., Gill J.S., Kausz A.T.: Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol 2002;13(5):1358-1364.
• 63. Gill J.S., Tonelli M., Johnson N., Pereira B.J.: Why do preemptive kidney transplant recipients have an allograft survival advantage? Transplantation 2004;78(6):873-879.
• 64. European Medicines Agency: Summary Information on a Referral Opinion Following an Arbitration Pursuant to Article 11 of Council Directive 75/319/EEC as Amended, for Glucophage/Glucophage Forte/Risidon/Dianben. Available http://www.ema.europa.eu/ docs/en_GB/document_library/Referrals_document/Glucophage_30/WC500011044.pdf (Accessed 14.05.2018)
• 65. US Food and Drug Administration: FDA Drug Safety Communication: FDA Revises Warnings Regarding Use of the Diabetes Medicine Metformin in Certain Patients with Reduced Kidney Function 2016. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM494140.pdf (Accessed 14.05.2018).
• 66. Pedrini M.T., Levey A.S., Lau J., Chalmers T.C., Wang P.H.: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 1996;124(7):627-632.
• 67. Pijls L.T., de Vries H., Donker A.J., van Eijk J.T.: The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Nephrol Dial Transplant. 1999;14:1445–1453.
• 68. Hansen H.P., Tauber-Lassen E., Jensen B.R., Parving H.H.: Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002;62(1):220-228.
• 69. Suckling R.J., He F.J., MacGregor G.A.: Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev 2012;(12):CD006763 doi:10.1002/14651858. CD006763.pub2.
• 70. Hall M.E., do Carmo J.M., da Silva A.A., Juncos L.A., Wang Z., Hall J.E.: Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 2014;7:75-88 doi:10.2147/IJNRD.S39739.
• 71. Sahni N., Gupta K.L., Rana S.V., Prasad R., Bhalla A.K.: Intake of antioxidants and their status in chronic kidney disease patients. J Ren Nutr 2012;22(4):389-399 doi:10.1053/j.jrn.2011.09.002.
• 72. Szulińska M, Stępień M, Kręgielska-Narożna M, Suliburska J, Skrypnik D, Bąk-Sosnowska M, Kujawska-Łuczak M, Grzymisławska M, Bogdański P.: Effects of green tea supplementation on inflammation markers, antioxidant status and blood pressure in NaCl-induced hypertensive rat model. Food Nutr Res 2017;61(1):1295525; doi: 10.1080/16546628.2017.1295525.
• 73. Szulińska M, Skrypnik D, Ratajczak M, Karolkiewicz J, Madry E, Musialik K, Walkowiak J, Jakubowski H, Bogdański P.: Effects of Endurance and Endurancestrength Exercise on Renal Function in Abdominally Obese Women with Renal Hyperfiltration: A Prospective Randomized Trial. Biomed Environ Sci 2016;29(10):706-712.
• 74. Baggio B., Budecovic A., Vortre M.D., Soller A., Bonseghin M., Fioretto P.: Effects of cigarette smoking on glomerular structure and function in type 2 diabetes patients. J Am Soc Nephrol 2002;13(11):2730-2736.
• 75. Śnit M., Burak W., Kuźniewicz R., Żukowska-Szczechowska E., Grzeszczak W.: Leczenie nerkozastępcze chorych na przewlekłą niewydolność nerek w przebiegu nefropatii cukrzycowej – dziesięcioletnia obserwacja. [Renal replacement therapy of chronic kidney disease in the course of diabetic nephropathy – 10-year observation]. Diabetol. Dosw. Klin. 2003;3(2);177-183 (in Polish).

Identyfikatory

DOI

10.32394/rpzh.2018.0037